Olema Pharmaceuticals (OLMA) Change in Accured Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Change in Accured Expenses data on file, last reported at $1.3 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $1.3 million, up 111.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.5 million (up 6474.3% YoY), and the FY2025 annual result was $11.0 million, down 1.95% from the prior year.
• Change in Accured Expenses eased to $1.3 million in Q1 2026 per OLMA's latest filing, from $3.6 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $12.7 million in Q2 2025 and troughed at -$11.2 million in Q1 2025.
• A 5-year average of $2.0 million and a median of $2.2 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses jumped 2481.42% in 2023, then sank 2684.16% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $3.7 million in 2022, then surged by 38.37% to $5.2 million in 2023, then sank by 56.87% to $2.2 million in 2024, then jumped by 62.83% to $3.6 million in 2025, then sank by 64.09% to $1.3 million in 2026.
• Business Quant data shows OLMA's Change in Accured Expenses at $1.3 million in Q1 2026, $3.6 million in Q4 2025, and $5.9 million in Q3 2025.